Castle Biosciences Q2 2025 Earnings Report

Castle Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.44
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Castle Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $71.53 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Castle Biosciences Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: Monday, August 4, 2025
• Conference Call Time: 4:30PM ET

Castle Biosciences (NASDAQ:CSTL) (NASDAQ:CSTL) is a molecular diagnostics company focused on developing and commercializing proprietary tests that help guide treatment decisions for patients with skin cancer and other dermatologic conditions. Since its founding, the company has leveraged genomic science and rigorous clinical studies to create assays that stratify disease risk, inform prognosis and enable more personalized care pathways. Castle Biosciences is headquartered in Friendswood, Texas, and operates under Clinical Laboratory Improvement Amendments (CLIA) certification to ensure the highest standards of laboratory quality and regulatory compliance.

The company’s core offerings include DecisionDx® tests, which utilize gene expression profiling to assess the probability of disease progression or recurrence. DecisionDx-Melanoma aids dermatologists and oncologists in evaluating the metastatic risk of cutaneous melanoma, while DecisionDx-Ductal Carcinoma In Situ (DCIS) supports treatment planning for early-stage breast cancer. Castle Biosciences also offers DecisionDx-SCC and DecisionDx-GIST assays to inform management of cutaneous squamous cell carcinoma and gastrointestinal stromal tumors, respectively. Each test is backed by peer-reviewed publications and ongoing clinical collaboration to refine risk stratification models.

In addition to its U.S. operations, Castle Biosciences has expanded service capabilities through partnerships with international laboratories and academic medical centers, aiming to broaden patient access to its diagnostic technologies. The company invests in research and development to advance molecular insights, and it maintains an in-house bioinformatics team that continuously enhances algorithm performance. Educational programs and digital tools are provided to healthcare providers to support the integration of genomic data into routine clinical practice.

Leadership at Castle Biosciences is anchored by President and Chief Executive Officer Scott D. Difrancesco, who brings more than two decades of experience in molecular diagnostics and life sciences commercialization. The executive team includes seasoned professionals in clinical operations, regulatory affairs and health economics, all committed to driving innovation and expanding the company’s footprint in precision medicine. Castle Biosciences continues to collaborate with key opinion leaders and healthcare organizations to validate its tests and demonstrate their value in improving patient outcomes.